← All organizations
A.O. Ospedale Maggiore di Lodi
Academic/Hospital
Also known as: A.O. Ospedale Maggiore di Lodi, Oncologia | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, UOS Milano, Italy, 20122 | IRCCS Ca' Granda Osp. Maggiore Policlinico | NICU. Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Milano, Milan, Italy, 20122 | OSPEDALE MAGGIORE LODI
Highest phase reached
Phase 4
First clinical trial
Jul 31, 2008Last known activity
Mar 11, 2025
Timeline
No events for the selected filters.
Drugs by trial phase (43 distinct, 32 trials)
Phase 4 (9 own, 0 via acquisition)
Phase 3 (10 own, 0 via acquisition)
Phase 2 (14 own, 0 via acquisition)
- methylprednisolone
- canrenone
- givinostat
- bone marrow derived mesenchymal stem cells
- pembrolizumab
- platelet-rich plasma
- lenvatinib
- nimotuzumab
- nitric oxide
- tocilizumab
- vinorelbine
- umbilical cord mesenchymal stem cells
- autologous bone marrow derived mesenchymal cells
- "ex vivo" expanded autologous human oral epithelium containing stem cells
Other trials (10 own, 0 via acquisition)
Indications
Studied for
- Acute Lung Injury
- Cataract
- Communicable Diseases
- Coronavirus Infections
- Dyspnea
- Eye Infections
- Infections
- Muscular Dystrophies
- Muscular Dystrophy, Duchenne
- Nephrosis
- Nephrotic Syndrome
- Pneumonia
- Pneumonia, Viral
- Respiratory Distress Syndrome
- Respiratory Distress Syndrome, Newborn
- Scleroderma, Diffuse
- Scleroderma, Localized
- Scleroderma, Systemic
- Severe Acute Respiratory Syndrome
- Shock
- Shock, Septic
- Stomach Neoplasms
- Syndrome
Recent trials (47)
- NCT07089511OfficialN/AMar 11, 2025
- NCT07089511Lead sponsorN/AMar 11, 2025
- NCT05846724Lead sponsorPhase 2Feb 1, 2024
- NCT06163833CollaboratorPhase 2Sep 19, 2023
- NCT06044194Lead sponsorPhase 3Mar 21, 2023
- NCT06044194Sponsor investigatorPhase 3Mar 21, 2023
- NCT06044194Reponsible party - principal investigatorPhase 3Mar 21, 2023
- NCT06661382OfficialPhase 1/Phase 2Jan 24, 2023
- NCT06661382Sponsor investigatorPhase 1/Phase 2Jan 24, 2023
- NCT06661382Lead sponsorPhase 1/Phase 2Jan 24, 2023
- NCT05874089Lead sponsorN/ANov 3, 2022
- NCT05874089Sponsor investigatorN/ANov 3, 2022
- NCT05874089Reponsible party - principal investigatorN/ANov 3, 2022
- NCT05482945Overall official - principal investigatorN/AMay 30, 2022
- NCT06131268Overall official - principal investigatorPhase 4Mar 1, 2022
Details
- Last known activity
- Mar 11, 2025